Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02045264 · ClinicalTrials.gov registry record · Phase 1
Open-label, Single-arm Study to Assess the Pharmacokinetics, Safety, and Tolerability of a Single Subcutaneous Dose of Icatibant in Healthy Japanese Volunteers
A Phase 1 study, sponsored by Shire.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT02045264 is a Phase 1 study that has completed, run by Shire. The registered enrollment target is 12 participants.
The verdict
NCT02045264, a Phase 1 study, has completed, sponsored by Shire.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
This is a single-dose study to evaluate the pharmacokinetics, safety, and tolerability of icatibant administered to adult Japanese subjects.
Interventions
- DRUG Icatibant (30 mg)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2014-02-21 |
| Est. Completion | 2014-02-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02045264
The ClinicalTrials.gov registry entry for NCT02045264 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shire, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Icatibant (30 mg) is the first listed.
NCT02045264 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02045264 about?
NCT02045264 is a clinical study titled "Open-label, Single-arm Study to Assess the Pharmacokinetics, Safety, and Tolerability of a Single Subcutaneous Dose of Icatibant in Healthy Japanese Volunteers". This is a single-dose study to evaluate the pharmacokinetics, safety, and tolerability of icatibant administered to adult Japanese subjects.
What is the current status of trial NCT02045264?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2014-02-21. Estimated completion is 2014-02-27.
What interventions are being tested in trial NCT02045264?
The interventions under investigation include: Icatibant (30 mg) (DRUG).
Who is sponsoring clinical trial NCT02045264?
This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.